The PROMIS10 patient-reported outcome measure is a valid and reliable tool in routine systemic lupus erythematosus care.
In patients with primary antiphospholipid syndrome, the presence of phosphatidylserine/prothrombin complex antibodies is associated with Raynaud phenomenon and migraine.
Complement pathway activation is associated with adverse pregnancy outcomes in women with systemic lupus erythematosus or antiphospholipid antibodies.
Data from the CARRA Legacy Registry show disability is common in patients with childhood-onset SLE.
Smoking is associated with risk for development of the anti-double-stranded DNA positive subtype of systemic lupus erythematosus.
The frequency, attribution, clinical, and autoantibody status of patients with lupus who developed cerebrovascular events are reported in this study.
Future research should look to improve perioperative management in people with systemic lupus erythematosus.
At this time, no serological test can distinguish neuropsychiatric events resulting from SLE activity from events resulting from other causes.
The risk for asthma may be increased in children born to mothers with systemic lupus erythematosus during pregnancy.
Patients with primary antiphospholipid syndrome and systemic lupus erythematosus-associated antiphospholipid syndrome have an almost 2.5-fold risk for development of atherosclerotic plaques in carotid and femoral arteries compared with healthy control patients.
Older patients with SLE are at a low risk for the development of proteinuria.
Lupus low disease activity state has been shown to be achievable and negatively associated with early damage accrual.
Investigators evaluated long-term outcomes with antimalarial use and organ damage, flares, disease activity, glucocorticoid use, and antimalarial associated retinopathy.
The SHARE initiative has formulated evidence-based recommendations for the diagnosis and treatment of lupus nephritis childhood-onset lupus nephritis.
Maternal systemic lupus erythematosus during pregnancy is associated with increased risk for asthma in children.
Switching from 1 antimalarial agent to a second may be beneficial in patients with cutaneous lupus erythematosus.
Atacicept may be safe and effective for lowering disease activity and severity in patients with active systemic lupus erythematosus.
Rates of SLE mortality have declined, but remain high relative to non-SLE mortality.
Anti-ficolin-2 autoantibodies may represent a biomarker for renal manifestations in patients with active systemic lupus erythematosus.
EULAR and ACR jointly funded and collaborated on creating a set of criteria that can be used to more accurately identify patients with SLE for inclusion in clinical trials.
Rheumatology Advisor Articles
- Raynaud Phenomenon, Migraine Linked to aPS/PT Antibodies in Primary Antiphospholipid Syndrome
- Then and Now: The Crisis of Physician Suicides
- Case Study: A Syncopal Episode During a Camping Trip
- Salivary Gland Ultrasound Scores Improved With Rituximab in Primary Sjogren's Syndrome
- Joint Replacement Rates in OA With Diabetes: Effects of COX-2 Inhibitors Plus Metformin
- FDA Advises Recall: Limbrel May Be Linked to Drug-Induced Liver Injury
- Allopurinol Use May Lower Risk for Peripheral Arterial Disease
- Managing Treatment Nonadherence in Rheumatic Diseases
- Optimal Fibromyalgia Management Includes Individualized, Multimodal Therapy
- Risk for COPD, Asthma Among Women With Rheumatoid Arthritis: Nurses' Health Study
- Aspirin Effective for VTE Prophylaxis After Hip, Knee Arthroplasty
- Short-Form Patient-Reported Outcomes Tool Effective in SLE
- Burnout Prevalence High Among Physicians in Single Health System
- Expert Insight: Discussing Sensitive Topics With Patients
- Increased HLA-B27 Associated With More Severe Sonographic Enthesitis in PsA